- Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor
- Disease models provide further evidence characterizing OV350 and its anticipated seizure reduction and neuroprotective profile, including its ability to reverse diazepam-resistant seizures
“We believe that new findings describing the pharmacokinetic and pharmacodynamic behavior of OV329 reinforce that it has a unique profile relative to prior GABA-aminotransferase inhibitors,” said
“We are additionally excited to present multiple refractory seizure models evaluating OV350, a direct KCC2 transporter activator, which suggests its potential properties as a monotherapy as well as a potentiator of benzodiazepines,” said Malhotra. “KCC2 is a novel mechanism of action which we believe has significant promise for the treatment of seizures.”
Posters to be presented on Ovid development programs are listed here:
OV329, A POTENTIAL NEXT-GENERATION GABA-AT INHIBITOR
Title: Evaluation of OV329, a Next-Generation GABA-AT Inhibitor, in the Intra-Amygdala Kainate Model of Mesial Temporal Lobe Epilepsy.
Session Date & Time:
Presenter:
Poster Number: #2.252
Title: Blocking of GABA-AT Activity by OV329 Selectively Alters Tonic and Phasic Inhibition in Dentate Gyrus Granule Cells.
Session Date & Time:
Presenter:
Poster Number: #2.253
Title: Low, Repeat Dosing of OV329 Enhances GABA-AT Inhibition in Rodent Brain: Relationship between Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects.
Session Date & Time:
Presenter:
Poster Number: # 3.255
OV350, A DIRECT ACTIVATOR OF POTASSIUM CHLORIDE CO-TRANSPORTER 2 (KCC2)
Title: Activation of KCC2 by OV350 Reverses Diazepam Resistant Seizures in Cdkl5 KO Mice.
Session Date & Time:
Presenter:
Poster Number: #2.250
Title: Potentiation of KCC2 shows Neuroprotective and Anti-inflammatory Effects in Kainic Acid-induced Refractory Status Epilepticus Model.
Session Date & Time:
Presenter:
Poster Number: #3.256
About
Forward-Looking Statements
This press release includes certain disclosures by Ovid that contain “forward-looking statements,” including, without limitation: statements regarding the potential use and development of OV329, OV888, OV350; the libraries of ROCK2 inhibitors and KCC2 compounds in Ovid’s portfolio; the potential therapeutic opportunity of OV329, OV888 and other ROCK2 inhibitors and OV350 and other KCC2 inhibitors; and the potential opportunity for soticlestat. You can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “expected,” “intends,” “may,” “plan,” “potentially,” “seek,” and “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid’s ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, or risks related to Ovid’s ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption “Risk Factors” in Ovid’s Quarterly Report on Form 10-Q filed with the
Contacts
Media:
1AB (on behalf of Ovid)
910-337-0707
J@1ABmedia.com
OR
Investors:
212-596-7231
ovid@argotpartners.com
Source:
2023 GlobeNewswire, Inc., source